CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

doi:10.1158/0008-5472.CAN-25-1835

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Cancer research - 16 Feb 2026

Long Szu-Aun, Todd Haley, Goodhart Grace, Chang Wen-Hsuan, Amparo Amber M, Bridgens Rachel, Dilly Julien, Park Se Jun, Beal Robert M, Shehadeh Sara M, Satyadi Megan A, Trivedi Vidushi K, Ackermann Sarah E, Mukherjee Raivath, Goodwin Craig M, Edwards A Cole, Stalnecker Clint A, Greis Kenneth D, Aguirre Andrew J, Hobbs G Aaron, Bryant Kirsten L, Ahmad Syed A, Cox Adrienne D, Der Channing J, Waters Andrew M

Abstract excerpt

KRAS inhibitors (KRASi) targeting various KRAS mutations have entered clinical trials for pancreatic cancer. Despite promising preliminary clinical responses, most patients relapse due to intrinsic or acquired resistance. Thus, combination treatments are essential to extend the efficacy of KRAS-targeted therapies. To further determine the genetic mechanisms of KRASi resistance, we performed KRASi-anchored...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to CRISPR-Cas Systems

Share to Drug Resistance, Neoplasm

Share to Erlotinib Hydrochloride

Share to Pancreatic Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 41248420
DOI: 10.1158/0008-5472.CAN-25-1835
PMCID: PMC13053059

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.PMID 41248420Read ↗

Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.Semantic proximity Read ↗

Survival of pancreatic cancer cells lacking KRAS functionSemantic proximity Read ↗

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity Read ↗

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.Semantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: new drugs on the horizon.Semantic proximity Read ↗

KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies.Semantic proximity Read ↗

Efficacy of CRISPR-Cas9 Gene Editing for Targeting KRAS Mutations in Pancreatic Cancer: A systematic reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.